GLP-1 Agonists: Benefits and Impact on Women’s Reproductive Health

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

GLP-1 agonists improve women's reproductive health by enhancing insulin sensitivity, aiding weight management, and regulating menstrual cycles, benefiting conditions like PCOS.

# GLP-1 Agonists and Women's Reproductive Health: What You Need to Know

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications originally developed to manage type 2 diabetes and obesity. Over the past decade, research has expanded our understanding of their effects beyond glucose regulation, including potential impacts on women's reproductive health. This article explores the relationship between GLP-1 agonists and female reproductive function, underlying mechanisms, clinical applications, and practical considerations.

---

What Are GLP-1 Agonists?

GLP-1 is an incretin hormone that stimulates insulin secretion, inhibits glucagon release, slows gastric emptying, and promotes satiety. GLP-1 receptor agonists mimic these effects by activating GLP-1 receptors, leading to improved blood glucose control and weight loss.

Common GLP-1 agonists include:

  • Exenatide (Byetta, Bydureon)
  • Liraglutide (Victoza, Saxenda)
  • Dulaglutide (Trulicity)
  • Semaglutide (Ozempic, Wegovy)

    • These drugs are typically administered via subcutaneous injection ranging from once daily to once weekly, depending on the formulation.

    ---

    GLP-1 Receptors and Female Reproductive Physiology

    Expression of GLP-1 Receptors in Reproductive Tissues

    GLP-1 receptors are expressed in various tissues, including the hypothalamus and pituitary gland, which play central roles in regulating reproductive hormones. Emerging evidence suggests GLP-1 receptor presence in the ovaries and uterus, indicating direct and indirect effects on female reproductive health.

    Impact on Hypothalamic-Pituitary-Gonadal (HPG) Axis

    The HPG axis governs menstrual cycles, ovulation, and fertility. GLP-1 agonists may influence this axis through:

  • Modulating gonadotropin-releasing hormone (GnRH) secretion
  • Altering luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels
  • Affecting sex steroids like estrogen and progesterone

    • These interactions might impact ovulatory function and menstrual regularity.

    ---

    Clinical Implications in Women's Reproductive Health

    Polycystic Ovary Syndrome (PCOS)

    PCOS is characterized by insulin resistance, hyperandrogenism, and ovulatory dysfunction. Since insulin resistance is pivotal in PCOS pathogenesis, GLP-1 agonists have been explored as treatment options.

  • Weight Loss and Insulin Sensitivity: GLP-1 agonists promote weight loss and improve insulin sensitivity, which can ameliorate PCOS symptoms.
  • Menstrual Regularity: Studies report improved menstrual cyclicity and ovulation after GLP-1 agonist therapy.

    • Evidence:

  • A 2018 randomized trial demonstrated that liraglutide (1.8 mg daily) combined with metformin improved weight, insulin resistance, and menstrual frequency in women with PCOS vs. metformin alone.
  • Semaglutide’s role is under investigation for similar benefits.

    • Fertility and Assisted Reproductive Technologies (ART)

    By improving metabolic profiles, GLP-1 agonists might enhance fertility outcomes:

  • Weight loss and better glycemic control can improve ovulation and oocyte quality.
  • Limited data suggest improved responses in women undergoing in vitro fertilization (IVF).

    • However, GLP-1 agonists are not yet approved or widely recommended specifically for fertility enhancement.

    Pregnancy Considerations

    GLP-1 agonists are classified as pregnancy category C or have insufficient human data. Use during pregnancy is generally not advised due to potential risks to the fetus.

  • Women planning pregnancy should consult providers to discontinue GLP-1 agonists appropriately.
  • Alternative management strategies for diabetes or weight control during pregnancy are preferred.

    • ---

    Practical Protocol and Dosing Information

    Common Dosing Regimens for GLP-1 Agonists in Women

    | Medication | Dose for Diabetes | Dose for Weight Management |

    |------------|-------------------|----------------------------|

    | Liraglutide (Victoza) | Start 0.6 mg daily, increase to 1.2–1.8 mg daily | Saxenda (liraglutide) up to 3 mg daily |

    | Semaglutide (Ozempic) | Start 0.25 mg weekly, increase to 0.5–1 mg weekly | Wegovy (semaglutide) up to 2.4 mg weekly |

    | Exenatide | 5 mcg twice daily to 10 mcg twice daily or 2 mg weekly (Bydureon) | Not approved for weight loss |

    Monitoring and Safety

  • Baseline assessment: Body weight, HbA1c, menstrual history, reproductive planning.
  • Regular follow-up: Monitor for side effects like nausea, pancreatitis risk, and thyroid tumors.
  • Contraception counseling: Important due to absence of safety data in pregnancy.
  • Discontinuation: Should be done under medical guidance if pregnancy is desired.

    • ---

    Evidence-Based Summary

  • GLP-1 agonists improve insulin sensitivity and promote modest weight loss, beneficial in PCOS management.
  • They may help restore menstrual regularity and ovulation in women with metabolic dysfunction.
  • The data remains limited regarding fertility enhancement and safety in pregnancy.
  • Long-term studies are needed to establish reproductive outcomes and safety profiles.
  • Use must be individualized and supervised by healthcare professionals.

    • ---

    Conclusion

    GLP-1 receptor agonists represent a promising adjunctive therapy for women with metabolic-related reproductive disorders such as PCOS, helping improve ovulatory function and menstrual regularity via weight loss and enhanced insulin sensitivity. However, these medications are not first-line treatments for infertility or reproductive health and require careful clinical consideration, especially in women planning pregnancy.

    Women interested in GLP-1 agonist therapy for reproductive health should consult endocrinologists or reproductive specialists to discuss benefits, risks, and personalized protocols. Proper medical supervision and ongoing monitoring are essential to optimize outcomes and ensure safety.

    ---

    Disclaimer: This article is for educational purposes only and should not replace professional medical advice. Always consult your healthcare provider before starting or stopping any medications, especially if you are pregnant, planning pregnancy, or have underlying health conditions.